ERIS LIFESCIENCES
|
ERIS LIFESCIENCES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 28.82 | 28.10 | 29.88 | 26.16 | 21.84 |
| CEPS(Rs) | 42.61 | 36.12 | 34.61 | 29.32 | 25.54 |
| DPS(Rs) | - | 7.35 | 6.01 | 5.50 | 2.87 |
| Book NAV/Share(Rs) | 189.75 | 161.28 | 140.25 | 115.81 | 95.26 |
| Tax Rate(%) | 7.93 | 7.53 | 8.23 | 9.98 | 10.52 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 31.91 | 30.41 | 34.77 | 34.60 | 34.25 |
| EBIT Margin(%) | 24.40 | 24.41 | 32.00 | 31.85 | 31.06 |
| Pre Tax Margin(%) | 20.39 | 22.92 | 31.70 | 31.69 | 30.85 |
| PAT Margin (%) | 18.78 | 21.20 | 29.09 | 28.53 | 27.61 |
| Cash Profit Margin (%) | 27.41 | 27.83 | 33.73 | 31.98 | 32.29 |
| Performance Ratios | |||||
| ROA(%) | 7.72 | 13.40 | 21.27 | 22.62 | 20.33 |
| ROE(%) | 16.63 | 18.25 | 23.33 | 24.78 | 24.28 |
| ROCE(%) | 12.36 | 17.30 | 25.29 | 27.60 | 25.44 |
| Asset Turnover(x) | 0.41 | 0.63 | 0.73 | 0.79 | 0.74 |
| Sales/Fixed Asset(x) | 0.55 | 0.90 | 1.33 | 1.25 | 1.18 |
| Working Capital/Sales(x) | -9.19 | 5.49 | 3.26 | 4.15 | 3.41 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.80 | 1.11 | 0.75 | 0.80 | 0.85 |
| Receivable days | 61.69 | 46.91 | 39.44 | 43.59 | 40.93 |
| Inventory Days | 27.66 | 25.78 | 27.78 | 24.03 | 25.85 |
| Payable days | 188.78 | 125.63 | 155.58 | 155.23 | 195.95 |
| Valuation Parameters | |||||
| PER(x) | 29.19 | 20.36 | 23.06 | 23.11 | 16.88 |
| PCE(x) | 19.74 | 15.84 | 19.91 | 20.61 | 14.43 |
| Price/Book(x) | 4.43 | 3.55 | 4.91 | 5.22 | 3.87 |
| Yield(%) | - | 1.28 | 0.87 | 0.91 | 0.78 |
| EV/Net Sales(x) | 6.36 | 5.07 | 6.95 | 6.74 | 4.60 |
| EV/Core EBITDA(x) | 18.29 | 15.61 | 18.31 | 18.59 | 12.86 |
| EV/EBIT(x) | 24.76 | 19.85 | 20.97 | 20.60 | 14.79 |
| EV/CE(x) | 2.40 | 2.83 | 4.43 | 4.80 | 3.44 |
| M Cap / Sales | 5.70 | 4.62 | 6.95 | 6.77 | 4.66 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 19.23 | 25.10 | 11.15 | 12.83 | 9.36 |
| Core EBITDA Growth(%) | 27.51 | 7.20 | 16.31 | 14.47 | 1.89 |
| EBIT Growth(%) | 19.78 | -3.50 | 12.60 | 18.83 | -1.99 |
| PAT Growth(%) | 6.12 | -7.79 | 14.26 | 19.77 | 1.84 |
| EPS Growth(%) | 2.54 | -5.94 | 14.23 | 19.78 | 3.27 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 1.06 | 0.38 | 0.02 | - | - |
| Current Ratio(x) | 0.91 | 1.62 | 2.51 | 2.27 | 2.43 |
| Quick Ratio(x) | 0.84 | 1.41 | 2.16 | 1.95 | 2.12 |
| Interest Cover(x) | 6.09 | 16.46 | 105.81 | 200.75 | 145.25 |
| Total Debt/Mcap(x) | 0.24 | 0.11 | - | - | - |
Compare Financial Ratios of peers of ERIS LIFESCIENCES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| ERIS LIFESCIENCES | ₹18,729.4 Cr | 1.7% | 7.8% | 46.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹431,352.0 Cr | 1.7% | -4.7% | 48.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹159,265.0 Cr | 4.4% | 3.1% | 66% | Stock Analytics | |
| CIPLA | ₹120,035.0 Cr | -0.9% | -1.7% | 17.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹101,286.0 Cr | -1% | -8.9% | 6.5% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹95,461.4 Cr | -1% | -4% | 48.4% | Stock Analytics | |
ERIS LIFESCIENCES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ERIS LIFESCIENCES | 1.7% |
7.8% |
46.5% |
| SENSEX | 1.8% |
-2.5% |
19.9% |
You may also like the below Video Courses
